IDYA
IDEAYA BIOSCIENCES INC
1 day chart
About IDYA
IDEAYA Biosciences, Inc. is a synthetic lethality-focused precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397 and IDE161. IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine adenosyltransferase 2a (MAT2A), inhibitor. IDE161, is its small molecule poly (ADP-ribose) glycohydrolase (PARG), inhibitor. IDE196 is its clinical-stage PKC inhibitor that the Company is evaluating as a synthetic lethal combination therapy. IDE397, a MAT2A inhibitor for patients with solid tumors having MTAP deletions. IDE161 is its clinical-stage, potent and selective small molecule inhibitor of PARG for patients having tumors with defined biomarkers based on genetic mutations and/or molecular signatures.
Buy US stocks in Australia starting with IDYA. Open an account and start investing today!
$1.97K
-
0.00%
797.02K
$31.60
$30.12
$30.67
$33.24
$13.29
IDYA FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in IDYA
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.